CD19 and myeloid sarcoma: Our study suggests that sustained CD19+ B-cell depletion is insufficient to predict clinical or radiological disease control in MS patients, and therefore may not be a useful guide in order to aid neurologists in tailoring BCDT reinfusion in this patient population.